Keyword: Samsung BioLogics

Celltrion Chairman Seo Jung-jin says the South Korean company will spend about $33 billion over a decade on its biologics and pharma businesses.

Eisai's stock plummets at AD failure; Keytruda has much upside in China, analysts say; Korea Exchange is dragged into Samsung accounting probe.

Samsung BioLogics has faced scrutiny of a biosimilars joint venture. Now, officials are looking more closely into the company's 2016 public listing.

Takeda's dengue vaccine clears phase 3; Pfizer launches China's first pay-for-performance deal in oncology; Aslan cuts 30% of its workforce.

Biologics CDMO Samsung BioLogics has kept up its frantic growth even as it deals with legal issues tied to its joint venture with Biogen.

Sun Pharma drops to six-year low; Takeda looks to sell emerging markets products; Immunochina raises $20 million for CAR-T push.

A court has suspended penalties imposed on Samsung BioLogics by South Korea's accounting regulator while prosecutors investigate.

India scrutinizes whistleblower case against Sun; FDA slaps warning letter on valsartan API maker; Eisai and UCL push anti-tau drug into the clinic.

A Chinese researcher claims is the world's first gene-edited babies; Takeda's Shire deal faces last-minute drama; Celltrion wins first Rituxan biosim nod.

Samsung is fighting back against charges that it improperly changed the method by which it valued a joint venture with Biogen.